Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges

Pediatric Blood and Cancer

Volumn 65, Issue 9, 2018, Pages

  Hulbert, Monica L ^a   Shenoy, Shalini ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

hematopoietic stem cell transplant; sickle cell disease; transplant eligibility

Indexed keywords

ACUTE TOXICITY; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MATCHED SIBLING DONOR; MEDICAL DECISION MAKING; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIBLING; SICKLE CELL ANEMIA; TRANSPLANTATION CONDITIONING; TREATMENT INDICATION; ADOLESCENT; CHILD; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); FEMALE; FORECASTING; GRAFT VERSUS HOST REACTION; HEALTH CARE DELIVERY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PROCEDURES; PROFESSIONAL-PATIENT RELATIONSHIP; RISK; STATISTICS AND NUMERICAL DATA; TRANSPLANTATION; TRENDS;

ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; CLINICAL DECISION-MAKING; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FORECASTING; GRAFT VS HOST DISEASE; HEALTH SERVICES ACCESSIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PATIENT SELECTION; PROFESSIONAL-PATIENT RELATIONS; RISK; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 85047660030     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.27263     Document Type: Review

References (105)

1. Bou-Maroun LM, Meta F, Hanba CJ, Campbell AD, Yanik GA. An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes. Pediatr Blood Cancer. 2017;65:e26758. https://doi.org/10.1002/pbc.26758
2. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447–3452.
3. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314:1593–1599.
4. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143:438–444.
5. Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107:201–206.
6. Lanzkron S, Carroll CP. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128:110–116.
7. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain. Curr Opin Hematol. 2011;18:158–165.
8. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–1322.
9. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–1672.
10. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403–408.
11. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354–2363.
12. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161:852–860.
13. National Heart, Lung, and Blood Institute, US Department of Health and Human Services. Evidence Based Management of Sickle Cell Disease: Expert Panel Report. Bethesda, MD: National Institutes of Health; 2014.
14. Creary SE, Chisolm DJ, Koch TL, Zigmont VA, Lu B, O'Brien SH. Hydroxyurea use in children with sickle cell disease: do severely affected patients use it and does it impact hospitalization outcomes. Pediatr Blood Cancer. 2016;63:844–847.
15. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785–789.
16. Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88:932–938.
17. Nottage KA, Hankins JS, Smeltzer M, et al. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS One. 2013;8:e72077.
18. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118:4985–4991.
19. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99:10–14.
20. Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98:608–614.
21. Fasano RM, Leong T, Kaushal M, Sagiv E, Luban NL, Meier ER. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. Transfusion. 2016;56:1707–1715.
22. Yee MEM, Josephson CD, Winkler AM, et al. Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia. Transfusion. 2017;57:2738–2746.
23. Woods D, Hayashi RJ, Binkley MM, Sparks GW, Hulbert ML. Increased complications of chronic erythrocytapheresis compared with manual exchange transfusions in children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2017;64.
24. Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013;60:828–835.
25. Hemker BG, Brousseau DC, Yan K, Hoffmann RG, Panepinto JA. When children with sickle-cell disease become adults: lack of outpatient care leads to increased use of the emergency department. Am J Hematol. 2011;86:863–865.
26. Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F. Age-related emergency department reliance in patients with sickle cell disease. J Emerg Med. 2015;49:513–522.
27. Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol. 2002;24:643–647.
28. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101.
29. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
30. King AA, Strouse JJ, Rodeghier MJ, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014;89:162–167.
31. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476–1481.
32. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062–1071.
33. Anderson LM, Allen TM, Thornburg CD, Bonner MJ. Fatigue in children with sickle cell disease: association with neurocognitive and social-emotional functioning and quality of life. J Pediatr Hematol Oncol. 2015;37: 84–589.
34. Clare A, FitzHenley M, Harris J, Hambleton I, Serjeant GR. Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence. Br J Haematol. 2002;119:567–571.
35. Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathology. 2017;49:1–9.
36. Babalola OE, Wambebe CO. When should children and young adults with sickle cell disease be referred for eye assessment. Afr J Med Med Sci. 2001;30:261–263.
37. Gil KM, Carson JW, Porter LS, Scipio C, Bediako SM, Orringer E. Daily mood and stress predict pain, health care use, and work activity in African American adults with sickle-cell disease. Health Psychol. 2004;23:267–274.
38. Okuyucu EE, Turhanoglu A, Duman T, Kaya H, Melek IM, Yilmazer S. Peripheral nervous system involvement in patients with sickle cell disease. Eur J Neurol. 2009;16:814–818.
39. Carroll CP, Lanzkron S. Chronic opioid therapy and central sensitization in sickle cell disease. Am J Prev Med. 2016;51:S69–77.
40. Kuo K, Caughey AB. Contemporary outcomes of sickle cell disease in pregnancy. Am J Obstet Gynecol. 2016;215:e501–505.
41. Huang AW, Muneyyirci-Delale O. Reproductive endocrine issues in men with sickle cell anemia. Andrology. 2017;5:679–690.
42. Ballas SK. Bauserman RL, McCarthy WF, Waclawiw MA, Multicenter Study of Hydroxyurea in Sickle Cell Anemia. The impact of hydroxyurea on career and employment of patients with sickle cell anemia. J Natl Med Assoc. 2010;102:993–999.
43. McClish DK, Smith WR, Levenson JL, et al. Comorbidity, pain, utilization, and psychosocial outcomes in older versus younger sickle cell adults: the PiSCES project. Biomed Res Int. 2017;2017:4070547.
44. Aisiku IP, Smith WR, McClish DK, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009;53:587–593.
45. Whiteman LN, Haywood C, Jr, Lanzkron S, Strouse JJ, Feldman L, Stewart RW. Primary care providers' comfort levels in caring for patients with sickle cell disease. South Med J. 2015;108:531–536.
46. Lunyera J, Jonassaint C, Jonassaint J, Shah N. Attitudes of primary care physicians toward sickle cell disease care, guidelines, and comanaging hydroxyurea with a specialist. J Prim Care Community Health. 2016.
47. Haywood C, Jr, Lanzkron S, Ratanawongsa N, Bediako SM, Lattimer-Nelson L, Beach MC. Hospital self-discharge among adults with sickle-cell disease (SCD): associations with trust and interpersonal experiences with care. J Hosp Med. 2010;5:289–294.
48. Lattimer L, Haywood C, Jr, Lanzkron S, Ratanawongsa N, Bediako SM, Beach MC. Problematic hospital experiences among adult patients with sickle cell disease. J Health Care Poor Underserved. 2010;21:1114–1123.
49. Treadwell MJ, Hassell K, Levine R, Keller S. Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research. Clin J Pain. 2014;30:902–914.
50. Haywood C, Jr, Diener-West M, Strouse J, et al. Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. J Pain Symptom Manage. 2014;48:934–943.
51. Evensen CT, Treadwell MJ, Keller S, et al. Quality of care in sickle cell disease: cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care. Medicine (Baltimore). 2016;95:e4528.
52. Aisiku IP, Penberthy LT, Smith WR, et al. Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study. J Natl Med Assoc. 2007;99:886–890.
53. Meier ER, Dioguardi JV, Kamani N. Current attitudes of parents and patients toward hematopoietic stem cell transplantation for sickle cell anemia. Pediatr Blood Cancer. 2015;62:1277–1284.
54. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT, 3rd. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311:780–783.
55. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–1556.
56. Walters MC, Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood. 1995;85:879–884.
57. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335:369–376.
58. Strocchio L, Zecca M, Comoli P, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015;169:726–736.
59. Chevret S, Verlhac S, Ducros-Miralles E, et al. Design of the DREPAGREFFE trial: a prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). Contemp Clin Trials. 2017; 62: 91–104.
60. Flanagan JM, Sheehan V, Linder H, et al. Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood. 2013;121:3237–3245.
61. Chaturvedi S, Bhatnagar P, Bean CJ, et al. Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia. Blood. 2017;130:686–688.
62. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22:1–6.
63. King AA, Kamani N, Bunin N, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015;90:1093–1098.
64. Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–272.
65. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749–2756.
66. Nickel RS, Seashore E, Lane PA, et al. Improved splenic function after hematopoietic stem cell transplant for sickle cell disease. Pediatr Blood Cancer. 2016;63:908–913.
67. Arnold SD, Brazauskas R, He N, et al. Clinical risks and healthcare utilization of haematopoietic cell transplantation for sickle cell disease in the U.S. using merged databases. Haematologica. 2017;102:1823–1832.
68. Nickel RS, Hendrickson JE, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease. Blood. 2014;124:861–866.
69. Mentzer WC, Heller S, Pearle PR, Hackney E, Vichinsky E. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol. 1994;16:27–29.
70. Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128:2561–2567.
71. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18:1265–1272.
72. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–4291.
73. Fitzhugh CD, Walters MC. The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia. Blood Adv. 2017;1:2563–2567.
74. Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665–673.
75. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14:1270–1278.
76. Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49:913–920.
77. Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017;130:1946–1948.
78. Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor-recipient chimerism and disease recurrence following hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23:2178–2183.
79. Abraham A, Cluster A, Jacobsohn D, et al. Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant. 2017;23:1587–1592.
80. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312:48–56.
81. Guilcher GM, Monagel D, Leaker M, et al. Alemtuzumab/low dose TBI conditioning facilitates stable long-term donor hematopoietic cell engraftment from sibling donors in children with sickle cell disease. Blood. 2017;130:4592.
82. Miglioretti DL, Johnson E, Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013;167:700–707.
83. Hansbury EN, Schultz WH, Ware RE, Aygun B. Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer. 2012;58:611–615.
84. Pelletier W, Hinds PS, Alderfer MA, Fairclough DL, Stegenga K, Pentz RD. Themes reported by families as important when proceeding with pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2014;61:1625–1631.
85. Bhatia M, Kolva E, Cimini L, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21:666–672.
86. Green NS, Bhatia M, Griffith EY, et al. Enhanced long-term brain magnetic resonance imaging evaluation of children with sickle cell disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:670–676.
87. Omondi NA, Ferguson SE, Majhail NS, et al. Barriers to hematopoietic cell transplantation clinical trial participation of African American and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol. 2013;35:289–298.
88. Thompson AL, Bridley A, Twohy E, et al. An educational symposium for patients with sickle cell disease and their families: results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. Pediatr Blood Cancer. 2013;60:1946–1951.
89. Creary S, Zickmund S, Ross D, Krishnamurti L, Bogen DL. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Res Notes. 2015;8:372.
90. Chakrabarti S, Bareford D. A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2007;39:447–451.
91. van Besien K, Koshy M, Anderson-Shaw L, et al. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001;28:545–549.
92. Koura DT, Horan JT, Langston AA, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013;19:1638–1649.
93. Gaziev J, Lucarelli G. Allogeneic hematopoietic cell transplants for thalassemia. In: Lazarus H, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, eds. Current Concepts and Controvercies in Hematopoietic Cell Transplantation. Cambridge University Press; 2016:513–523.
94. Madden LM, Hayashi RJ, Chan KW, et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transplant. 2016;22:1467–1472.
95. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361:2309–2317.
96. Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016;22:441–448.
97. Thompson D, Harrington Y, de la Fuente J. The incidence of posterior reversible encephalopathy syndrome is increased in BMT for haemoglobinopathies. Blood. 2013;122:4579.
98. Pegelow CH, Coangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death with relative hypertension in sickle cell anemia. Am J Med. 1997;102:171–177.
99. Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point. Am Health Drug Benefits. 2010;3:15–23.
100. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439.
101. Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175:141–153.
102. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–855.
103. Kanter J, Walters MC, Hsieh M, et al. Interim results from a phase 1/2 clinical study of Lentiglobin gene therapy for severe sickle cell disease. Blood. 2017;130:527.
104. Issaragrisil S, Kunacheewa C. Matched sibling donor hematopoietic stem cell transplantation for thalassemia. Curr Opin Hematol. 2016;23:508–514.
105. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–820.